| Quarterly Financials | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 622 | 572 | 573 | 547 | 579 | 503 | 526 | 529 | 539 |
| Expenses | 368 | 393 | 377 | 370 | 400 | 367 | 404 | 397 | 364 |
| EBITDA | 254 | 179 | 195 | 177 | 179 | 137 | 122 | 132 | 175 |
| Operating Profit % | 29 % | 24 % | 23 % | 21 % | 22 % | 21 % | 23 % | 23 % | 32 % |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 244 | 169 | 186 | 167 | 169 | 127 | 113 | 122 | 165 |
| Tax | 54 | 46 | 34 | 30 | 33 | 24 | 30 | 31 | 46 |
| Net Profit | 190 | 123 | 152 | 138 | 137 | 103 | 82 | 91 | 120 |
| EPS in ₹ | 82.78 | 53.37 | 65.95 | 59.79 | 59.31 | 44.81 | 35.69 | 39.64 | 51.89 |
Sanofi
Sanofi
4,780.60
-26.50
(-0.55%)
There are new updates from the company18 hours ago
Show All
Key Fundamentals
Market Cap
11,071.10 Cr
EPS
179.46
PE Ratio
27.78
Dividend Yield
2.44 %
Industry
Healthcare 52 Week High
6,899.00
52 Week Low
4,623.50
PB Ratio
12.79
Debt to Equity
0.02
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from3 analysts
Actual
Company News
View All News
Sanofi India Declares Interim Dividend of ₹275 per Share18 hours ago
Sanofi India's Board of Directors declared an interim dividend of ₹275 per equity share with a face value of ₹10 for the year 2025. The company has set November 7, 2025 as the record date to determine shareholders eligible to receive the interim dividend payment.
Sanofi India Plans Growth Through Chronic Care, Specialty Products, and Local Manufacturing2 days ago
Sanofi India is targeting steady expansion through its chronic and specialty drug portfolios. The company plans to launch new diabetes treatments and vaccines while optimizing costs through local manufacturing and supply chain integration.
Sanofi India reported a 7.5% decline in net profit to ₹76 crore for the third quarter ended September 30, compared to ₹82 crore in the previous year. Revenue from operations fell 9.3% to ₹475.4 crore from ₹524 crore year-over-year. However, EBITDA increased 12% to ₹134 crore, with operating margin improving to 28% from 23%, driven by cost efficiency measures and favorable product mix. The company is streamlining its portfolio to focus on core therapeutic areas including diabetes and cardiovascular treatments. The board declared an interim dividend of ₹75 per share for FY25, with November 7 as the record date. Shares remained largely unchanged at ₹4,747.00 following the results announcement, with the stock gaining 22% year-to-date.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,690.70 | #1 4,08,702.70 | 39.00 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 57.70 | |
6,738.00 | 1,76,669.30 | 77.66 | 9,712.00 | 18.67 | 2,191 | 26.74 | 69.64 | |
1,501.30 | 1,24,402.20 | 22.32 | 28,409.50 | 7.12 | 5,291 | 3.71 | 39.14 | |
3,560.10 | 1,21,921.60 | 60.16 | 11,539.40 | 6.99 | 1,911 | 19.91 | 47.71 | |
2,384.00 | 1,00,985.50 | 51.41 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 35.82 | |
1,197.60 | 1,00,337.30 | #1 17.42 | 33,741.20 | 16.73 | 5,725 | -0.38 | 33.79 | |
974.45 | 99,229.80 | 20.81 | 23,511.00 | 18.55 | 4,615 | 2.60 | 39.78 | |
1,963.50 | 88,875.30 | 24.10 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 53.35 | |
5,506.50 | 66,059.70 | 28.22 | 13,458.30 | 3.70 | 2,216 | 21.39 | 52.15 | |
1,138.90 | 64,033.40 | 19.68 | 32,345.60 | 9.43 | 3,484 | -10.24 | 62.57 |
Growth Rate
Revenue Growth
-1.34 %
Net Income Growth
-13.96 %
Cash Flow Change
100.30 %
ROE
1.50 %
ROCE
-2.71 %
EBITDA Margin (Avg.)
-
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2023 | 2024 |
| Total Assets | 1,715 | 1,612 |
| Fixed Assets | 315 | 313 |
| Current Assets | 1,248 | 1,127 |
| Capital Work in Progress | 16 | 18 |
| Investments | 0 | 0 |
| Other Assets | 1,384 | 1,281 |
| Total Liabilities | 1,715 | 1,612 |
| Current Liabilities | 651 | 719 |
| Non Current Liabilities | 48 | 32 |
| Total Equity | 1,015 | 861 |
| Reserve & Surplus | 992 | 838 |
| Share Capital | 23 | 23 |
Cash Flow
| Cash Flow | 2023 | 2024 |
| Net Cash Flow | -610 | -111 |
| Investing Activities | 38 | -180 |
| Operating Activities | 230 | 462 |
| Financing Activities | -878 | -392 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 6.80 % | 0.00 % | 6.11 % | 5.81 % | 5.78 % | 5.63 % | 5.57 % | 5.61 % | 5.57 % |
| DIIs | 17.16 % | 17.39 % | 17.65 % | 19.03 % | 18.65 % | 18.60 % | 18.27 % | 19.21 % | 19.47 % | 19.66 % | 21.69 % | 22.47 % | 23.08 % | 22.79 % | 22.82 % | 22.93 % | 23.02 % | 23.06 % | 22.29 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.97 % | 7.09 % | 7.21 % | 7.01 % | 7.65 % | 7.92 % | 8.81 % | 9.13 % | 9.29 % | 8.89 % | 8.60 % | 8.09 % | 7.97 % | 8.31 % | 8.21 % | 8.33 % | 8.38 % | 8.33 % | 9.08 % |
| Others | 15.48 % | 15.12 % | 14.74 % | 13.56 % | 13.30 % | 13.09 % | 12.53 % | 11.26 % | 10.85 % | 11.05 % | 2.51 % | 9.04 % | 2.44 % | 2.69 % | 2.79 % | 2.70 % | 2.63 % | 2.61 % | 2.67 % |
| No of Share Holders | 0 | 48,465 | 53,567 | 51,646 | 50,916 | 59,276 | 64,542 | 73,734 | 76,694 | 71,513 | 68,598 | 62,870 | 61,849 | 67,662 | 66,211 | 66,401 | 68,196 | 66,790 | 71,395 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 71 | 84 | 349 | 365 | 490 | 570 | 167 | 117 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.37 | 1.44 | 5.58 | 4.63 | 6.53 | 10.15 | 2.06 | 2.04 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 07 Nov 2025 |  Dividend | ₹ 75.00 /share | 07 Nov 2025 | 4,746.30 | 4,780.05 |
| 21 Apr 2021 | Dividend | ₹ 125.00 /share | 19 Apr 2021 | 7,919.85 | 7,682.05 |
| 21 Apr 2021 | Dividend | ₹ 240.00 /share | 19 Apr 2021 | 7,919.85 | 7,682.05 |
| 16 Apr 2022 | Dividend | ₹ 181.00 /share | 12 Apr 2022 | 7,136.45 | 7,300.40 |
| 16 Apr 2022 | Dividend | ₹ 309.00 /share | 12 Apr 2022 | 7,136.45 | 7,300.40 |
| 26 Apr 2022 |  Annual General Meeting | NA | 26 Apr 2022 | 7,136.45 | 6,979.40 |
| 08 Aug 2022 | Dividend | ₹ 193.00 /share | 05 Aug 2022 | 6,749.00 | 6,542.60 |
| 29 Apr 2023 | Dividend | ₹ 194.00 /share | 28 Apr 2023 | 5,399.30 | 5,572.25 |
| 29 Apr 2023 | Dividend | ₹ 183.00 /share | 28 Apr 2023 | 5,399.30 | 5,572.25 |
| 11 May 2023 | Annual General Meeting | NA | 11 May 2023 | 5,399.30 | 5,700.45 |
| 18 Dec 2023 |  Extraordinary General Meeting | NA | 18 Dec 2023 | 7,804.20 | 8,054.90 |
| 07 Mar 2024 | Dividend | ₹ 50.00 /share | 07 Mar 2024 | 9,208.85 | 8,529.75 |
| 03 May 2024 | Dividend | ₹ 117.00 /share | 03 May 2024 | 9,208.85 | 8,679.45 |
| 14 May 2024 | Annual General Meeting | NA | 14 May 2024 | 9,208.85 | 7,995.05 |
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 7,024.25 | 6,583.05 |
| 27 Feb 2025 | Quarterly Result Announcement | NA | 27 Feb 2025 | 5,358.40 | 5,059.65 |
| 25 Apr 2025 | Dividend | ₹ 117.00 /share | 25 Apr 2025 | 5,059.65 | 6,570.50 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 5,754.70 | 5,928.60 |
| 15 May 2025 | Annual General Meeting | NA | 15 May 2025 | 5,568.15 | 6,042.35 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 5,955.65 | 5,881.95 |
| 29 Oct 2025 | Quarterly Result Announcement | NA | 29 Oct 2025 | 4,772.95 | 4,746.30 |
Announcements
Intimation Of Record Date
18 hours ago
18 hours agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Investor Presentation2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Dividend Updates2 days ago
2 days agoFinancial Results For The Quarter And Nine Months Ended 30Th September 20252 days ago
2 days agoBoard Meeting Outcome for Financials Results For The Quarter Ended 30Th September 2025 And Recommendation Of Interim Dividend2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Cessation4 days ago
4 days agoBoard Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On 27Th October 20254 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Change in Directorate4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
8 days agoBoard Meeting Intimation for Consideration And Approval Of Unaudited Financial Statements For The Quarter And Nine-Months Ended 30Th September 2025 And Declaration Of Interim Dividend For The Year 2025 If Any.8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationOct 18, 2025
Oct 18, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Oct 16, 2025
Oct 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Appointment of Company Secretary and Compliance OfficerSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerSep 25, 2025
Sep 25, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 11, 2025
Sep 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 23, 2025
Aug 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-RetirementJul 31, 2025
Jul 31, 2025Financial Results For The Quarter And Half-Year Ended 30Th June 2025Jul 31, 2025
Jul 31, 2025Board Meeting Outcome for Financial Results For The Quarter And Half-Year Ended 30Th June 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 29, 2025
Jul 29, 2025Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Statements For The Quarter And Half-Year Ended 30Th June 2025Jul 18, 2025
Jul 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 16, 2025
Jul 16, 2025Board Meeting Outcome for Outcome Of Board Meeting Of The Company Held On 16Th July 2025Jul 16, 2025
Jul 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
May 30, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.May 24, 2025
May 24, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 24, 2025
May 24, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 22, 2025
May 22, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportMay 15, 2025
May 15, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
May 14, 2025Financials Results For The Quarter Ended 31St March 2025May 14, 2025
May 14, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On Wednesday 14Th May 2025May 14, 2025
May 14, 2025Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Statements For The Quarter Ended 31St March 2025May 09, 2025
May 09, 2025Mutual Fund Holdings
Aditya Birla Sun Life Small Cap Fund Direct-Growth 
SBI Mid Cap Direct Plan-Growth 
Baroda BNP Paribas Midcap Fund Direct-Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Bandhan BSE Healthcare Index Fund Direct-Growth 
HDFC BSE 500 Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
LIC MF Small Cap Fund Direct - Growth 
Axis Nifty 500 Index Fund Direct-Growth 
Baroda BNP Paribas Health and Wellness Fund Direct-Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 48.44
ATR(14)
Less Volatile 86.42
STOCH(9,6)
Neutral 50.64
STOCH RSI(14)
Overbought 92.04
MACD(12,26)
Bullish 25.91
ADX(14)
Strong Trend 36.92
UO(9)
Bearish 39.36
ROC(12)
Uptrend And Accelerating 1.15
WillR(14)
Neutral -43.81
About Sanofi
Sanofi India Limited is a pharmaceutical company primarily engaged in manufacturing and trading drugs and pharmaceuticals. It operates manufacturing facilities in Goa and Ankleshwar, Gujarat, and sells products through independent distributors mainly in India. The company focuses on five therapeutic areas: diabetes, epilepsy, cardiology, allergy, and pain care. Key products include Lantus (insulin), Combiflam (pain relief), Amaryl (anti-diabetic), Allegra (allergy), Cardace (cardiovascular), and Toujeo (long-acting insulin). Sanofi India is majority-owned by Sanofi and its subsidiary Hoechst GmbH, holding 60.37% of its paid-up share capital. The company has undergone several name changes and acquisitions, including the purchase of Universal Medicare's nutraceutical business in 2011. In 2021, Sanofi India sold its Nutraceuticals business to Universal Nutriscience Private Limited, and in 2022-23, its Consumer Healthcare Business was demerged into a wholly-owned subsidiary.
Chairperson NameAditya Narayan
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
